1. Immunology and Inflammation
  2. Stem Cells and Regenerative Medicine

Maresin 1 repletion improves muscle regeneration after volumetric muscle loss

  1. Jesus A Castor-Macias
  2. Jacqueline A Larouche
  3. Emily C Wallace
  4. Bonnie D Spence
  5. Alec Eames
  6. Pamela Duran
  7. Benjamin A Yang
  8. Paula M Fraczek
  9. Carol A Davis
  10. Susan V Brooks
  11. Krishna Rao Maddipati
  12. James F Markworth
  13. Carlos A Aguilar  Is a corresponding author
  1. University of Michigan-Ann Arbor, United States
  2. Wayne State University, United States
  3. Purdue University West Lafayette, United States
https://doi.org/10.7554/eLife.86437
Share this article
Cite this article
  1. Jesus A Castor-Macias
  2. Jacqueline A Larouche
  3. Emily C Wallace
  4. Bonnie D Spence
  5. Alec Eames
  6. Pamela Duran
  7. Benjamin A Yang
  8. Paula M Fraczek
  9. Carol A Davis
  10. Susan V Brooks
  11. Krishna Rao Maddipati
  12. James F Markworth
  13. Carlos A Aguilar
(2023)
Maresin 1 repletion improves muscle regeneration after volumetric muscle loss
eLife 12:e86437.
https://doi.org/10.7554/eLife.86437
  2. Download BibTeX
  3. Download .RIS

Abstract

The acute traumatic or surgical loss of skeletal muscle, known as volumetric muscle loss (VML), is a devastating type of injury that results in exacerbated and persistent inflammation followed by fibrosis. The mechanisms that mediate the magnitude and duration of the inflammatory response and ensuing fibrosis after VML remain understudied and as such, the development of regenerative therapies has been limited. To address this need, we profiled how lipid mediators, which are potent regulators of the immune response after injury, varied with VML injuries that heal or result in fibrosis. We observed that non-healing VML injuries displayed increased pro-inflammatory eicosanoids and a lack of pro-resolving lipid mediators. Treatment of VML with a pro-resolving lipid mediator synthesized from docosahexaenoic acid, called Maresin 1, ameliorated fibrosis through reduction of neutrophils and macrophages and enhanced recovery of muscle strength. These results expand our knowledge of the dysregulated immune response that develops after VML and identify a novel immuno-regenerative therapeutic modality in Maresin 1.

Data availability

Sequencing data have been deposited in GEO under accession codes GSE215808

The following data sets were generated

Article and author information

Author details

  1. Jesus A Castor-Macias

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. Jacqueline A Larouche

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9380-3547

  3. Emily C Wallace

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Bonnie D Spence

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Alec Eames

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Pamela Duran

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  7. Benjamin A Yang

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  8. Paula M Fraczek

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. Carol A Davis

    Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Susan V Brooks

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Krishna Rao Maddipati

    Department of Pathology, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. James F Markworth

    Department of Animal Sciences, Purdue University West Lafayette, West Lafayette, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5348-1464

  13. Carlos A Aguilar

    Department of Biomedical Engineering, University of Michigan-Ann Arbor, Ann Arbor, United States
    For correspondence
    caguilar@umich.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3830-0634

Funding

National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30 AR069620)

  • Carlos A Aguilar

Congressionally Directed Medical Research Programs (W81XWH2010336)

  • Carlos A Aguilar

Congressionally Directed Medical Research Programs (W81XWH2110491)

  • Carlos A Aguilar

3M Foundation

  • Carlos A Aguilar

American Federation for Aging Research

  • Carlos A Aguilar

National Science Foundation (2045977)

  • Carlos A Aguilar

Defense Advanced Research Projects Agency (D20AC0002)

  • Carlos A Aguilar

Hevolution Foundation

  • Carlos A Aguilar

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mice were fed normal chow ad libitum and housed on a 12:12 hour light-dark cycle under UM veterinary staff supervision. Allprocedures were approved by the Institutional Animal Care and Use Committee (IACUC) andwere in accordance with the U.S. National Institute of Health (NIH).

Copyright

© 2023, Castor-Macias et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,256
    views
  • 196
    downloads
  • 2
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jesus A Castor-Macias
  2. Jacqueline A Larouche
  3. Emily C Wallace
  4. Bonnie D Spence
  5. Alec Eames
  6. Pamela Duran
  7. Benjamin A Yang
  8. Paula M Fraczek
  9. Carol A Davis
  10. Susan V Brooks
  11. Krishna Rao Maddipati
  12. James F Markworth
  13. Carlos A Aguilar
(2023)
Maresin 1 repletion improves muscle regeneration after volumetric muscle loss
eLife 12:e86437.
https://doi.org/10.7554/eLife.86437

Share this article

https://doi.org/10.7554/eLife.86437

Categories and tags

Research organism

Further reading

    1. Immunology and Inflammation

    Role of hepatocyte RIPK1 in maintaining liver homeostasis during metabolic challenges

    Weigao Zhang, Hu Liu ... Dan Weng
    Research Article

    As a central hub for metabolism, the liver exhibits strong adaptability to maintain homeostasis in response to food fluctuations throughout evolution. However, the mechanisms governing this resilience remain incompletely understood. In this study, we identified Receptor interacting protein kinase 1 (RIPK1) in hepatocytes as a critical regulator in preserving hepatic homeostasis during metabolic challenges, such as short-term fasting or high-fat dieting. Our results demonstrated that hepatocyte-specific deficiency of RIPK1 sensitized the liver to short-term fasting-induced liver injury and hepatocyte apoptosis in both male and female mice. Despite being a common physiological stressor that typically does not induce liver inflammation, short-term fasting triggered hepatic inflammation and compensatory proliferation in hepatocyte-specific RIPK1-deficient (Ripk1-hepKO) mice. Transcriptomic analysis revealed that short-term fasting oriented the hepatic microenvironment into an inflammatory state in Ripk1-hepKO mice, with up-regulated expression of inflammation and immune cell recruitment-associated genes. Single-cell RNA sequencing further confirmed the altered cellular composition in the liver of Ripk1-hepKO mice during fasting, highlighting the increased recruitment of macrophages to the liver. Mechanically, our results indicated that ER stress was involved in fasting-induced liver injury in Ripk1-hepKO mice. Overall, our findings revealed the role of RIPK1 in maintaining liver homeostasis during metabolic fluctuations and shed light on the intricate interplay between cell death, inflammation, and metabolism.

    1. Genetics and Genomics
    2. Immunology and Inflammation

    Paradoxical dominant negative activity of an immunodeficiency-associated activating PIK3R1 variant

    Patsy R Tomlinson, Rachel G Knox ... Robert K Semple
    Research Article

    PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.

    1. Immunology and Inflammation

    Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases

    Shih-Wen Huang, Yein-Gei Lai ... Nan-Shih Liao
    Research Article

    Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.